search scholar.google.com.

Papers Published

1. Amiram, M; Luginbuhl, KM; Li, X; Feinglos, MN; Chilkoti, A, A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection., Journal of controlled release : official journal of the Controlled Release Society, vol. 172 no. 1 (November, 2013), pp. 144-151 [23928357], [doi] .
   (last updated on 2024/07/16)

   Abstract:
   Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of diseases; however, their short half-life dictates multiple and frequent injections causing undesirable side effects. Herein, we describe a novel peptide delivery system that seeks to combine the attractive features of prolonged circulation time with a prolonged release formulation. This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to a thermally responsive, elastin-like-polypeptide (ELP) that undergoes a soluble-insoluble phase transition between room temperature and body temperature, thereby forming an injectable depot. We synthesized a set of GLP-1-ELP fusions and verified their proteolytic stability and potency in vitro. Significantly, a single injection of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5 days, 120 times longer than an injection of the native peptide. These findings demonstrate the unique advantages of using ELPs to release peptide-ELP fusions from a depot combined with enhanced systemic circulation to create a tunable peptide delivery system.